Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 25,000 Shares of Stock

Posted by George Bondi on Nov 7th, 2026

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Kevin McCulloch sold 25,000 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $12.49, for a total transaction of $312,250.00. Following the sale, the insider directly owned 1,559,208 shares in the company, valued at approximately $19,474,507.92. The trade was a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

On Monday, November 2nd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.23, for a total value of $153,450.00.
On Thursday, October 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $9.41, for a total value of $141,150.00.
On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $10.00, for a total value of $250,000.00.
On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total transaction of $127,350.00.

Xeris Biopharma Stock Performance

Shares of NASDAQ:XERS opened at $15.20 on Friday. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The business’s 50 day moving average price is $9.62 and its 200-day moving average price is $7.62. The firm has a market capitalization of $2.77 billion, a PE ratio of -303.94 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $15.21.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The firm had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. As a group, equities research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

More Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on XERS. Piper Sandler reaffirmed a “neutral” rating and set a $12.00 price objective (up from $8.00) on shares of Xeris Biopharma in a research note on Friday. Oppenheimer restated an “outperform” rating and set a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a report on Friday. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. HC Wainwright upped their price target on Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a research report on Friday. Finally, Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.20.

Read Our Latest Report on Xeris Biopharma

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Chicago Partners Investment Group LLC increased its position in shares of Xeris Biopharma by 16.3% during the third quarter. Chicago Partners Investment Group LLC now owns 13,286 shares of the company’s stock valued at $136,000 after acquiring an additional 1,861 shares during the last quarter. AlphaCentric Advisors LLC boosted its position in shares of Xeris Biopharma by 4.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock worth $464,000 after purchasing an additional 1,940 shares during the period. Allworth Financial LP boosted its position in shares of Xeris Biopharma by 86.4% during the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after purchasing an additional 2,000 shares during the period. Jacksonville Wealth Management LLC increased its holdings in Xeris Biopharma by 11.8% in the 3rd quarter. Jacksonville Wealth Management LLC now owns 19,000 shares of the company’s stock valued at $182,000 after purchasing an additional 2,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Xeris Biopharma by 7.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 33,266 shares of the company’s stock valued at $332,000 after buying an additional 2,190 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.